Shuji Sato

Title: The Innovations of Shuji Sato

Introduction

Shuji Sato is a prominent inventor based in Narita, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of three patents to his name, Sato's work has the potential to impact medical science and organ transplantation.

Latest Patents

One of Sato's latest patents is titled "Monoclonal antibody having immunosuppressive activity or antigen binding fragment thereof." This invention relates to a monoclonal antibody that exhibits excellent immunosuppressive activity. More specifically, it involves a monoclonal antibody or an antigen binding fragment that binds to a peptide with the amino acid sequence SSVLYGGPPSAA. This antibody demonstrates a higher binding affinity for core histone compared to histone H1. Another significant patent is "Anti-histone H1 monoclonal antibody and hybridoma for the production thereof." This invention discloses anti-histone H1 monoclonal antibodies and hybridomas, which are useful for suppressing, predicting, or diagnosing transplant rejection in organ transplantation.

Career Highlights

Shuji Sato has worked with notable organizations such as Amateras Pharma Inc. and Josai University Corporation. His experience in these institutions has allowed him to collaborate with other experts in the field and further his research in immunology and biotechnology.

Collaborations

Some of Sato's coworkers include Takeshi Goto and Shigeru Goto. Their collaborative efforts have contributed to the advancements in the development of monoclonal antibodies and related technologies.

Conclusion

Shuji Sato's innovative work in the field of monoclonal antibodies showcases his dedication to advancing medical science. His patents reflect a commitment to improving organ transplantation outcomes and enhancing immunosuppressive therapies.